TRISPORT PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
TRISPORT PHARMA
Largest movements
- Cash -€12,892
down €12,892 (-49.2%), from €26,195 to €13,302
mainly Trade debts (-€11,668) and Stocks and contracts (-€8,960)
- Stocks and contracts +€8,960
up €8,960 (+21.9%), from €40,974 to €49,934
- Receivables within one year +€8,620
up €8,620 (+73.3%), from €11,761 to €20,382
of which Trade receivables: +€10,719
- Profit (loss) carried forward +€21,663
up €21,663 (+32.3%), from -€67,008 to -€45,346
- Trade debts -€11,668
down €11,668 (-93.8%), from €12,439 to €770
- Other debts -€5,306
down €5,306 (-6.7%), from €79,384 to €74,078
- Gross operating margin +€24,045
up €24,045, from -€6,534 to €17,511
- Financial income +€6,468
up €6,468 (+5,176%), from €125 to €6,593
- Financial charges -€3,845
down €3,845 (-70.1%), from €5,488 to €1,643
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €81,643 | €86,332 | +€4,688 | +5.7% |
| Fixed assets | 21/28 | €2,713 | €2,713 | = | 0.0% |
| Financial fixed assets | 28 | €2,713 | €2,713 | = | 0.0% |
| Current assets | 29/58 | €78,930 | €83,618 | +€4,688 | +5.9% |
| Stocks and contracts in progress | 3 | €40,974 | €49,934 | +€8,960 | +21.9% |
| Stocks | 30/36 | €40,974 | €49,934 | +€8,960 | +21.9% |
| Amounts receivable within one year | 40/41 | €11,761 | €20,382 | +€8,620 | +73.3% |
| Trade receivables | 40 | €8,608 | €19,327 | +€10,719 | +125% |
| Other amounts receivable | 41 | €3,153 | €1,054 | -€2,099 | -66.6% |
| Cash at bank and in hand | 54/58 | €26,195 | €13,302 | -€12,892 | -49.2% |
| Total equity and liabilities | 10/49 | €81,643 | €86,332 | +€4,688 | +5.7% |
| Equity | 10/15 | -€10,179 | €11,484 | +€21,663 | |
| Contributions | 10/11 | €48,339 | €48,339 | = | 0.0% |
| Reserves | 13 | €8,490 | €8,490 | = | 0.0% |
| Non-distributable reserves | 130/1 | €4,834 | €4,834 | = | 0.0% |
| Reserves not available under the articles | 1311 | €4,834 | €4,834 | = | 0.0% |
| Distributable reserves | 133 | €3,656 | €3,656 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€67,008 | -€45,346 | +€21,663 | +32.3% |
| Amounts payable | 17/49 | €91,823 | €74,848 | -€16,975 | -18.5% |
| Amounts payable within one year | 42/48 | €91,823 | €74,848 | -€16,975 | -18.5% |
| Trade debts | 44 | €12,439 | €770 | -€11,668 | -93.8% |
| Suppliers | 440/4 | €12,439 | €770 | -€11,668 | -93.8% |
| Other amounts payable | 47/48 | €79,384 | €74,078 | -€5,306 | -6.7% |
| Non-recurring operating income | 76A | €6,518 | €0 | -€6,518 | -100% |
| Other operating charges | 640/8 | €657 | €799 | +€142 | +21.6% |
| Gross operating margin | 9900 | -€6,534 | €17,511 | +€24,045 | |
| Operating profit (loss) | 9901 | -€7,190 | €16,712 | +€23,903 | |
| Financial income | 75/76B | €125 | €6,593 | +€6,468 | +5,176% |
| Recurring financial income | 75 | €125 | €6,593 | +€6,468 | +5,176% |
| Financial charges | 65/66B | €5,488 | €1,643 | -€3,845 | -70.1% |
| Recurring financial charges | 65 | €5,488 | €1,643 | -€3,845 | -70.1% |
| Profit (loss) for the period before taxes | 9903 | -€12,553 | €21,663 | +€34,216 | |
| Profit (loss) for the period | 9904 | -€12,553 | €21,663 | +€34,216 | |
| Profit (loss) for the period to be appropriated | 9905 | -€12,553 | €21,663 | +€34,216 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 13 October 2026 via checked.be.